first-line treatment in egfr mutant non-small cell lung cancer: is there a best option?

Clicks: 313
ID: 228300
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #55 of 207 articles by views in international journal of heat and technology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 207 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
First generation or second generation EGFR tyrosine kinase inhibitors are currently the standard of care for the first-line management of non-small cell lung cancer (NSCLC) patients with activating mutations within the kinase domain of the epidermal growth factor receptor gene (1, 2). Resistance to targeted therapy can develop after 9–11 months (3–8). Third generation inhibitors were developed to target the EGFR T790M clone, which is the most common dominant second site resistance mutation after first or second generation inhibitors. Osimertinib received full FDA approval for the second-line treatment of advanced NSCLC based on a phase III study comparing the compound to chemotherapy. Recent data demonstrates an important impact for osimertinib in the front-line space based on results comparing the compound to first-generation erlotinib or gefitinib therapy.
Reference Key
bulbul2018frontiersfirst-line Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Ajaz Bulbul;Ajaz Bulbul;Hatim Husain
Journal international journal of heat and technology
Year 2018
DOI
10.3389/fonc.2018.00094
URL
http://journal.frontiersin.org/article/10.3389/fonc.2018.00094/full
Keywords
lung cancer targeted therapy osimertinib Oncology epidermal growth factor receptor including cancer and carcinogens tumors

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.